Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.39 |
| ▸ | RRM1 | P23921 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 2/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14246731 | 0.84 | NAAA (0.42) | EPHX1NAAARRM1DPP7GBA1 | |
| SCHEMBL18214282 | 0.83 | NAAA (0.41) | EPHX1NAAARRM1DPP7GBA1 | |
| SCHEMBL18214274 | 0.83 | NAAA (0.41) | EPHX1NAAARRM1DPP7GBA1 | |
| SCHEMBL20161696 | 0.81 | EPHX2 (0.42) | EPHX1NAAARRM1DPP7METAP2 | |
| SCHEMBL20161930 | 0.81 | EPHX2 (0.42) | EPHX1NAAARRM1DPP7METAP2 | |
| SCHEMBL20161460 | 0.78 | GJB2 (0.46) | — | |
| SCHEMBL18971270 | 0.75 | LGALS8 (0.33) | — | |
| SCHEMBL60344 | 0.72 | TLR4 (0.50) | EPHX1 | |
| SCHEMBL15870614 | 0.72 | TLR4 (0.50) | EPHX1 | |
| SCHEMBL60345 | 0.72 | TLR4 (0.50) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661475-A1 | WNT COMPOSITIONS AND METHODS OF PROCESS FROM SERUM-FREE CULTURING CONDITIONS | Ankasa Regenerative Therapeutics, Inc. (US) | 2020-06-10 | — | — | EP | claimed |
| EP-3454891-A1 | EMULSION ADJUVANT FOR INTRAMUSCULAR, INTRADERMAL AND SUBCUTANEOUS ADMINISTRATION | The Regents of The University of Michigan (US) | 2019-03-20 | — | — | EP | claimed |
| WO-2019028186-A1 | WNT COMPOSITIONS AND METHODS OF PROCESS FROM SERUM-FREE CULTURING CONDITIONS | ANKASA REGENERATIVE THERAPEUTICS, INC. (US) | 2019-02-07 | — | — | WO | claimed |
| WO-2018204669-A1 | INTRAVENOUS IMMUNOGLOBULIN COMPOSITIONS SPECIFIC FOR RESPIRATORY SYNCYTIAL VIRUS AND METHODS OF MAKING AND USING THE SAME | NANOBIO CORPORATION (US) | 2018-11-08 | — | — | WO | claimed |
| WO-2017196979-A1 | EMULSION ADJUVANT FOR INTRAMUSCULAR, INTRADERMAL AND SUBCUTANEOUS ADMINISTRATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-11-16 | — | — | WO | claimed |
| WO-2015085143-A2 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM (US) | 2015-06-11 | — | — | WO | claimed |
| US-20240165221-A1 | CORONAVIRUS VACCINE FORMULATIONS | NOVAVAX, INC. | 2024-05-23 | — | — | US | disclosed |
| CN-110691609-B | Methods and compositions for inducing an immune response against clostridium difficile | 诺瓦瓦克斯股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11938179-B2 | Methods and compositions for inducing immune responses against Clostridium difficile | NOVAVAX, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11896662-B2 | Multivalent influenza nanoparticle vaccines | NOVAVAX, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11896664-B2 | Corona virus vaccine formulations | NOVAVAX, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| WO-2023102448-A2 | CORONAVIRUS VACCINE FORMULATIONS | NOVAVAX, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| EP-4181880-A1 | ANHYDROUS ANTIMICROBIAL TOPICAL FORMULATIONS AND METHODS OF USE THEREOF | NSC - Nano Sono Cooperation Ltd. (IL) | 2023-05-24 | — | — | EP | disclosed |
| WO-2006097537-A2 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | disclosed |
| EP-1608392-A2 | PAPANICOLAU STAINING PROCESS | Cytyc Corporation (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1551376-A2 | IMMUNOMODULATORY COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF | Dynavax Technologies Corporation (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004086945-A2 | PAPANICOLAU STAINING PROCESS | CYTYC CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004014322-A2 | IMMUNOMODULATORY COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-1284982-A2 | METHOD FOR TREATING PLANT MATERIAL, COMPOSITIONS COMPRISING N-ACYLGLUCOSAMINE DERIVATIVES, USE OF SAID COMPOUNDS AS BIOLOGICALLY PROTECTIVE AGENTS, AND TREATED PLANT MATERIAL, IN PARTICULAR SEEDS | UNIVERSITE PIERRE ET MARIE CURIE PARIS VI (FR) | 2003-02-26 | — | — | EP | disclosed |
| WO-2001087902-A2 | METHOD FOR TREATING PLANT MATERIAL, COMPOSITIONS COMPRISING N-ACYLGLUCOSAMINE DERIVATIVES, USE OF SAID COMPOUNDS | UNIVERSITE PIERRE ET MARIE CURIE (PARIS VI) (FR) | 2001-11-22 | — | — | WO | disclosed |